Rocket Pharmaceuticals financials
$2.59−0.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$46.9M | -$48.5M | -$44.0M | -$52.2M | -$71.1M | -$64.4M | -$62.7M | -$69.4M | -$73.7M | -$67.4M | -$63.3M | -$65.4M |
| Net income | $123.2M | -$47.6M | -$42.5M | -$50.3M | -$68.9M | -$61.3M | -$60.3M | -$66.7M | -$69.6M | -$62.1M | -$59.7M | -$61.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $1.08 | $-0.42 | $-0.38 | $-0.45 | $-0.62 | $-0.56 | $-0.62 | $-0.71 | $-0.74 | $-0.66 | $-0.64 | $-0.75 |
| EBITDA | -$45.4M | -$46.9M | -$42.4M | -$49.7M | -$65.6M | -$61.9M | -$60.9M | -$67.6M | -$71.9M | -$65.7M | -$61.9M | -$64.2M |
| Operating cash flow | -$39.6M | -$45.4M | -$34.8M | -$50.4M | -$49.0M | -$55.8M | -$46.9M | -$52.1M | -$53.8M | -$56.9M | -$29.3M | -$57.1M |
| Free cash flow | -$39.6M | -$45.5M | -$34.9M | -$50.5M | -$49.0M | -$56.2M | -$47.3M | -$53.7M | -$55.8M | -$58.9M | -$34.0M | -$61.8M |
| Diluted shares | 114.5M | 112.1M | 111.8M | 111.6M | 111.0M | 110.1M | 97.8M | 94.2M | 93.7M | 93.5M | 93.5M | 82.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $224.5M | $49.6M | $77.6M | $75.9M | $32.8M | $49.8M |
| Short-term investments | $59.2M | $94.8M | $111.4M | $146.8M | $238.7M | $268.4M |
| Total debt | $21.3M | $21.3M | $21.3M | $21.3M | $21.3M | $21.3M |
| Total assets | $423.1M | $285.4M | $330.4M | $368.0M | $421.0M | $471.1M |
| Total liabilities | $54.3M | $47.4M | $53.2M | $54.4M | $66.8M | $58.9M |
| Shareholders' equity | $368.8M | $238.0M | $277.2M | $313.7M | $354.2M | $412.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology